Evaluation of Factors Influencing Use of RoActemra as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO

Trial Profile

Evaluation of Factors Influencing Use of RoActemra as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ACT-SOLO
  • Sponsors Roche
  • Most Recent Events

    • 08 Nov 2017 Results of pooled analysis from SPARE-1 and Act-solo studies assessing factors influencing the use of TCZ in Mono or in combination with DMARDs (Combo) in real-life practice in RA patients, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 12 Oct 2017 Results (n=884) of pooled analysis from SPARE-1 and Act-solo studies, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 17 Jun 2017 Results of pooled analysis (n=1494) of three observational studies (PEPS, Spare-1 and Act-solo), presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top